Condition: ANCA Associated Vasculitis (AAV) · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| University Of Colorado | Aurora, Colorado, United States | Recruiting |
| Mayo Clinic Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Michigan Med University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Recruiting |
| Oregon Health Sciences University | Portland, Oregon, United States | Recruiting |
| Baylor University Medical Center | Dallas, Texas, United States | Recruiting |
| Houston Methodist Hospital | Houston, Texas, United States | Recruiting |
| LDS Hospital | Salt Lake City, Utah, United States | Recruiting |
| Novartis Investigative Site | Salvador, Estado de Bahia, Brazil | Recruiting |
+ 23 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06868290